Long-term results of the AIEOP MH’96 childhood Hodgkin’s lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapy

References

• Donaldson SS, Link MP. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin’s disease. J Clin Oncol. 1987;5:742–749.
   PubMed Web of Science ®Google Scholar
• Ekert H, Waters D, Smith PJ, et al. Treatment with MOPP or ChlVPP chemotherapy only for all stages of childhood Hodgkin’s disease. J Clin Oncol. 1988;6:1845–1850.
   PubMed Web of Science ®Google Scholar
• Fryer CJ, Hutchinson RJ, Krailo M, et al. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin’s disease in children: a report from the Children’s Cancer Study Group. J Clin Oncol. 1990;8:1971–1980.
   PubMed Web of Science ®Google Scholar
• Jenkin D, Doyle J, Berry M, et al. Hodgkin’s disease in children: treatment with MOPP and low-dose, extended-field irradiation without laparotomy: late results and toxicity. Med Pediatr Oncol. 1990;18:265–272.
   PubMedGoogle Scholar
• Weiner MA, Leventhal B, Brecher ML, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol. 1997;15:2769–2779.
   PubMed Web of Science ®Google Scholar
• Hudson M, Greenwald C, Thompson E, et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin’s disease. J Clin Oncol. 1993;11:100–108.
   PubMed Web of Science ®Google Scholar
• Hunger S, Link M, Donaldson S. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience. J Clin Oncol. 1994;12:2160–2166.
   PubMed Web of Science ®Google Scholar
• Schellong G. Treatment of children and adolescent with Hodgkin’s disease: the experience of the German-Austrian Paediatric Study Group. Bailleres Clin Haematol. 1996;9:619–634.
   PubMed Web of Science ®Google Scholar
• Mefferd JM, Donaldson SS, Link MP. Pediatric Hodgkin’s disease: pulmonary, cardiac, and thyroid function following combined therapy. Int J Radiat Oncol Biol Phys. 1989;16:679–685.
   PubMed Web of Science ®Google Scholar
• Beaty O III, Hudson MM, Greenwald C, et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin’s disease. J Clin Oncol. 1995;13:603–609.
   PubMed Web of Science ®Google Scholar
• Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study Cohort. J Clin Oncol. 2009;27:2356–2362.
   PubMed Web of Science ®Google Scholar
• Oberlin O, Leverger G, Pacquement H, et al. Low dose radiation therapy and reduced chemotherapy in childhood Hodgkin’s disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol. 1992;10:1602–1608.
   PubMed Web of Science ®Google Scholar
• Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin’s disease: response adapted chemotherapy with etoposide, bleomycin, vinblastine and prednisone before low dose radiation therapy: results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol. 2000;18:1500–1507.
   PubMed Web of Science ®Google Scholar
• Ruhl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin’s disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys. 2001;51:1209–1218.
   PubMed Web of Science ®Google Scholar
• Wolden SL, Chen L, Kelly KM, et al. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin’s Lymphoma—A Report from the Children’s Oncology Group. J Clin Oncol. 2012;30:3174–3180.
   PubMed Web of Science ®Google Scholar
• Friedmann AM, Hudson MM, Weinstein HJ, et al. Treatment of unfavorable childhood Hodgkin’s disease with VEPA and low-dose, involved-field radiation. J Clin Oncol. 2002;20:3088–3094.
   PubMed Web of Science ®Google Scholar
• Dörffel W, Rühl U, Lüders H, et al. Treatment of children and adolescents with Hodgkin Lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol. 2013;31:1562–1568.
   PubMed Web of Science ®Google Scholar
• Hudson MM, Krasin M, Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin’s disease. J Clin Oncol. 2004;22:4541–4550.
   PubMed Web of Science ®Google Scholar
• Kung FH, Schwartz CL, Ferree CR, et al. POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA1 Hodgkin disease: a report from the Children’s Oncology Group. J Pediatr Hematol Oncol. 2006;28:362–368.
   PubMed Web of Science ®Google Scholar
• Vecchi V, Pileri S, Burnelli R, et al. Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients. Cancer. 1993;72:2049–2057.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic disease of the haematopoietic and lymphoid tissue: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia; November 1997. Histopathology. 2000;36:69–87.
   Google Scholar
• Terezakis SA, Hudson MM, Constine LS. Hodgkin lymphoma. In: Halperin EC, Constine LS, Tarbell NJ, Kun LE, editors. Pediatric radiation oncology. Philadelphia (PA): Lippincott Williams & Wilkins; 2011. p. 137–165.
   Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
   Web of Science ®Google Scholar
• Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York (NY): Wiley; 1980
   Google Scholar
• Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist. 1988;16:1141–1154.
   Web of Science ®Google Scholar
• Schellong G, Oberlin O, Vecchi V, et al. Hodgkin’s disease in children: combined modality treatment involving OPPA/COPP chemotherapy. A European study in the International Society of Pediatric Oncology (SIOP). Leuk Lymphoma. 1997;15:2241–2253.
   Google Scholar
• Schellong G, Potter R, Bramswig J, et al. High cure rates and reduced long term toxicity in pediatric Hodgkin’s disease: The German-Austrian multicenter trial DAL-HD-90. J Clin Oncol. 1999;17:3736–3744.
   PubMed Web of Science ®Google Scholar
• Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report form the Children’s Oncology Group. Blood. 2011;117:2596–2603.
   PubMed Web of Science ®Google Scholar
• Mauz-Körholz C, Hasenclever D, Dörffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010;28:3680–3686.
   PubMed Web of Science ®Google Scholar
• Hodgson DC, Hudson MM, Constine L. Pediatric Hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Semin Radiat Oncol. 2007;17:230–242.
   PubMed Web of Science ®Google Scholar
• Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114:2051–2059.
   PubMed Web of Science ®Google Scholar
• Tebbi CK, Mendenhall N, London WB, et al. Response-dependent and reduced treatment in lower risk hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children’s Oncology Group. Pediatric Blood Cancer. 2012;59:1259–1265.
   PubMed Web of Science ®Google Scholar
• Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;373:2499–2511.
   PubMed Web of Science ®Google Scholar
• Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366:399–408.
   PubMed Web of Science ®Google Scholar
• Körholz D, Wallace WH, Landman-Parker J. Euro-Net-Paediatric Hodgkin’s Lymphoma Group (Euro-Net-PHL-C1): First international inter-group study for classical Hodgkin’s lymphoma in children and adolescents. http://clinicaltrials.gov/ct/show/ NCT00433459:2012
   Google Scholar
• Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin’s disease. J Clin Oncol 2007;25:332–337.
   PubMed Web of Science ®Google Scholar
• Engert A, Plütschow A, Elch HT, et al. Reduced treatment intensity in patients with early-staged Hodgkin’s lymphoma. N Engl J Med. 2010;363:640–652.
   PubMed Web of Science ®Google Scholar
• Gerber NK, Atoria CL, Elkin EB, et al. Characteristics and outcomes of patients with nodular Lymphocyte-Predominant Hodgkin Lymphoma versus those with classical Hodgkin Lymphoma: a population-based analysis. In J Radiat Oncol Biol Phys. 2015;92:76–83.
   PubMed Web of Science ®Google Scholar
• Fan Z, Natkunam Y, Bair E, et al. Characterization of variant patterns of Nodular Lymphocyte Predominant Hodgkin Lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003;27:1346–1356.
   PubMed Web of Science ®Google Scholar
• Shankar AG, Kirkwood AA, Hall GW, et al. Childhood and adolescent nodular lymphocyte predominant Hodgkin lymphoma – A review of clinical outcome base on the histological variants. Br J Haematol. 2015;171:254–262.
   PubMed Web of Science ®Google Scholar
• Gloghini A, Bosco A, Ponzoni M, et al. Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathological and clinical implications. Expert Rev Hematol. 2015;8:217–223.
   PubMed Web of Science ®Google Scholar
• Dieckmann K, Potter R, Hofmann J, et al. Does bulky disease at diagnosis influence outcome in childhood Hodgkin’s disease and require higher radiation doses? Results from the German-Austrian pediatric multicenter trial DAL-HD-90. Int J Radiation Oncology Biol Phys. 2003;56:644–652.
   PubMed Web of Science ®Google Scholar
• Punnet A, Tsang RW, Hodgson DC. Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol. 2010;20:30–44.
   PubMed Web of Science ®Google Scholar
• Schellong G, Riepenhausen M, Creutzig U, et al. Low risk of secondary leukemias after chemotherapy without Mechloretamine in childhood Hodgkin’s Disease. German-Austrian Pediatric Hodgkin’s Disease Group. J Clin Oncol. 1997;15:2247–2253.
   PubMed Web of Science ®Google Scholar
• Meadows AT, Obringer AC, Marrero O, et al. Second malignant neoplasms following childhood Hodgkin’s disease: treatment and splenectomy as risk factors. Med Pediatr Oncol. 1989;17:477–484.
   PubMedGoogle Scholar
• O’Brien MM, Donaldson SS, Balise RR, et al. Second malignant neoplasms in survivors of pediatric Hodgkin’s Lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol. 2010;28:1232–1239.
   PubMed Web of Science ®Google Scholar
• Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program. 2011;2011:323–329.
   PubMed Web of Science ®Google Scholar
• Dörffel W, Riepenhausen M, Lüders H, et al. Secondary malignancies following treatment for Hodgkin’s lymphoma in childhood and adolescence. Dtsch Arztebl Int. 2015;112:320–327.
   PubMed Web of Science ®Google Scholar